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A 59-year-old male with invasive squamous cell carcinoma of the left preauricular region, treated with several chemotherapy
regimensandradiationtherapy, wasadmittedforrecurrent syncopalepisodes.Hewasfoundtobesuﬀeringfromneurocardiogenic
reﬂex-mediated syncope secondary to mechanical compression of the carotid baroreceptors and glossopharyngeal nerve by the
tumor. We discuss the pathophysiology of this case and the available treatment options.
1.Case
A 59-year-old Caucasian male with invasive squamous cell
carcinoma of the left pre-auricular region was admitted for
recurrent syncope over a period of four weeks. He was previ-
ously treated with radiation therapy and two chemotherapy
agents, Cisplatin and Cetuximab. He described brief prodro-
mal symptoms of lightheadedness and diaphoresis prior to
each episode. He regained consciousness in less than one
minute and quickly returned to his baseline mental status.
Upon arrival to the emergency room after his ﬁrst episode,
his pulse was 65 beats per minute (bpm) and his blood
pressure was recorded as 64/42mmHg. He was managed
with aggressive ﬂuid resuscitation, including three liters of
intravenousﬂuids, and Trendelenburg positioning. Afterthis
ﬁrstepisode,follow-upbloodpressure recordingswerein the
normal range within the ﬁrst one to two hours. 24 hours
later, he was no longer symptomatic and was back to his
baseline physical and mental status. On a second occasion
he was more profoundly aﬀected, and his ﬁrst systolic blood
pressure recorded in the emergencyroom was 46 mmHg and
hispulse ranged from 46–57bpm.Uponpresentationduring
this event he was confused and his blood pressure took
longer to recover despite similar treatment with intravenous
ﬂuid resuscitation and Trendelenburg positioning. However,
similar to the ﬁrst episode, 24 hours later he was back to his
baseline.
On no occasion was his syncope associated with head
turning or neck compression. He did have longstanding
neuropathic pain located in the posterior nasopharynx and
the left side of his face. As his disease had progressed, he
also developed pain with swallowing; however, there was
no exacerbation in his symptoms surrounding the syncopal
episodes. Several events occurred while he was supine.
Further testing including orthostatic blood pressure
measurements, electrolyte measurements, an electrocardio-
gram, and echocardiogram revealed no abnormalities. A
Holter monitor recording preceding one of his syncopal
episodes showed sinus pauses of up to 2.1 seconds. These
pauses were frequent and were associated with prodromal
symptoms of diaphoresis and lightheadedness (Figure 1(a)).
A few minutes later, he had a rapid drop in his sinus rate to
a junctional rhythm at 33bpm (Figure 1(b))t h a tc u l m i n a t e d
in a syncopalepisode. Both ofthese symptomatic recordings,
although nocturnal, began in the supine, but awake state.
Formal tilt table testing and gentle carotid massage was not
feasible due to the lability of his vital signs. Repeat head and
neck computed tomography (CT) scan showed progression
of his tumor, now completely encasing his left internal
carotid artery at its bifurcation from the left common2 Cardiology Research and Practice
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Figure 1: (a) Holter monitor recording showing sinus bradycardia at 42bpm with sinus pauses of up to 2.1 seconds, corresponding to his
prodromal symptoms while awake. (b) Holter monitor recording during a syncopal episode showing a drop in heart rate to 33bpm.
carotid artery (Figure 2). In addition, the tumor abutted the
glossopharyngealnerveatthepointofexitfr omtheposterior
aspect of the base of his skull. We concluded that the
patientwas suﬀering from neurocardiogenic reﬂex-mediated
syncope,secondary tomechanical compression by thetumor
of the carotid baroreceptors and the glossopharyngeal nerve.
This syndrome has also been called a parapharyngeal space
lesion syncope.
Hewasplacedonmidodrine,ﬂudrocortisone,andsertra-
line to help alleviate his symptoms; however, he continued to
have syncopal episodes while hospitalized that became pro-
gressively more resistant to ﬂuid resuscitation. For example,
duringtheﬁrst twoeventshe experienced,his bloodpressure
recovered within the ﬁrst one to two hours of aggressive
ﬂuid resuscitation. However, during later hospitalizations,
despite the same interventions his blood pressure remained
i nt h eh y p o t e n s i v er a n g ef o rh o u r s .D u r i n gt w od i ﬀerent
episodes,hewasgivenatropinetohelpincreasehisheartrate.
His heart rate increased appropriately with this intervention;
however, hypotension persisted, thus demonstrating that the
vasodilatory component of his neurally mediated syncope
was playing a dominant role in his events. His primary
oncology team determined that he had a poor prognosis
and did not have any more chemotherapy or radiation
therapyoptionsavailabletotreathisprogressive cancer.After
discussion with him, he was discharged with home hospice.
2.Discussion
2.1. Neurally Mediated (Reﬂex) Syncope and Carotid Barore-
ceptors. Neurally mediated, or reﬂex, syncope is the term
used to describe a reﬂex response that leads to systemic
hypotension and bradycardia. The trigger for this response
can be varied in individual patients. This case illustrates a
particular severe cause of neurally mediated syncope due to
mechanical encroachment on the carotid baroreceptors and
glossopharyngeal nerve.
The carotid baroreceptors are located at the internal
carotid artery, close to their bifurcation oﬀ the common
Figure 2: CT scan of the patient’s head, axial image. The red
arrow shows tumor encasing the internal carotid artery. The blue
arrow shows tumor inﬁltrating the skull base where CN IX exits
the jugular foramen. CN IX is not visualized clearly because of the
invading tumor.
carotid artery. They are innervated by the Sinus Nerve of
Hering, which is a branch of the glossopharyngeal nerve,
cranial nerve (CN) IX. Sensory ﬁbers arise from the carotid
body and join the other components of CN IX at the inferior
hypoglossal ganglion. The central processes of these neurons
enter the skull via the jugular foramen. In its passage to
the jugular foramen, CN IX passes between the internal
jugular vein and internal carotid artery. It descends in
front of the internal carotid artery and beneath the styloid
process and the muscles connected with it. After entering
the skull, CN IX eventually synapses in the nucleus tractus
solitarus (NTS), which in turn modulates activity of both
the sympathetic and parasympathetic neurons in medulla.Cardiology Research and Practice 3
The medulla ultimately regulates autonomic control of the
heart and blood vessels.
Maximal carotid sinus sensitivity normally occurs near a
mean arterial pressure (MAP) of approximately 100mmHg.
Increases in MAP increase baroreceptor ﬁring and decreases
in MAP lead to decreases in baroreceptor ﬁring. Carotid
sinus sensitivity is such that even very small changes in
arterial pressure around this set point can signiﬁcantly alter
receptor ﬁring, and in turn, tightly up regulate or down
regulate autonomic control of the heart and peripheral
vasculature [1]. In this individual, progressive disease led
to tumor compression of the internal carotid artery, and
the mechanical pressure caused an increase in baroreceptor
ﬁring. His medulla responded by increasing parasympa-
thetic outﬂow and decreasing sympathetic outﬂow. Under
normal physiologic conditions, baroreceptor ﬁring has a
tonic inhibitory inﬂuence on sympathetic outﬂow from the
medulla, and in this case, the sympathetic outﬂow was
decreased still further.
This patient’s tumor also encroached upon CN IX
as it exited the skull base and thus aﬀected a second
anatomical component of the neutrally mediated reﬂex.
Direct tumor ingrowth at CN IX at the jugular foramen
interrupted the sensory ﬁbers that run along the nerve
aﬀecting parasympathetic and sympathetic outﬂow from the
medulla. The combination of bradycardia and peripheral
vasculature vasodilatation that occurs as a result of the surge
in parasympathetic outﬂow and decrease in sympathetic
stimulation culminated in his syncopal episodes.
Another pathogenic mechanism underlying the associ-
ation between glossopharyngeal neuralgia and syncope is
thought to be related to the close relationship that exists
between CN IX and CN X [2]. Neurosurgical research sug-
gests that ephapses, or artiﬁcial synapses, develop between
CN IX and CN X, or that anomalous communications
develop between the nucleus tractus sollitarus and the
nucleusambiguouscentrally[3].Thepr esenceofanirritative
lesion might thus give rise to “cross talk” between the above
circuits, thereby inducing bradycardia with or without a
decreaseinperipheralresistance, throughpossiblemediation
of the vagus nerve and carotid baroreceptor, respectively [4].
Evidence for cross talk between nerve ﬁbers is supported by
experimental ﬁndings [5].
Thus, it is likely a combination of several factors
including direct tumor invasion on the carotid body and
CN IX, and possible developmentof anomalous connections
centrally involving CN X that led to our patient’s syncopal
episodes. The inexorable progression of his symptoms and
theirincreasing refractorinesstoresuscitationcorrespondsto
the progressive state of his tumor.
2.2. Treatment Options for Neurally Mediated (Reﬂex) Syn-
cope. The European Society for Cardiology oﬀered a recent
update on its guidelines for the management of syncope
[6]. The initial steps for treating patients suﬀering from
the common form of neurally mediated (reﬂex) syncope
include reassurance and education about their syndrome.
Other simple interventions such as educating patients to
avoid trigger events, teaching them to recognize and respond
to premonitory symptoms, and modifying or discontinuing
medications that may cause hypotension have also proven
to be beneﬁcial. Patients that suﬀer from frequent syncopal
episodes may require additional pharmacologic treatment.
Many drugs have been used for treatment of the various
forms of neurally mediated syncope, including beta blockers
and anticholinergic agents; however, the evidence for beneﬁt
in randomized clinical trials is lacking. Midodrine, an agent
that stimulates alpha-1 adrenergic receptors, has shown
more promise in selected patients, particularly those with
predominant vasodilatory responses. Results from two small
open-label randomized studies that were done on patients
who suﬀered from recurrent neurally mediated syncope
showed that midodrine was eﬀective in reducing the number
of syncopal and presyncopal episodes over the short term,
and its use signiﬁcantly improved patients’ quality of life
[7, 8].
The use of selective serotonin reuptake inhibitors (SSRI)
has also been studied in patients with neurally medi-
ated syncope. Serotonin (5-hydroxytryptamine), along with
several other neurotransmitters, may play an important
role in eliciting reﬂex syncopal reactions. Experimental
animal models in rats [9] have shown that intracerebral
serotonin inhibits sympathetic neural outﬂow during acute
hemorrhage while increasing adrenal sympathetic stimu-
lation. In rabbits, blocking serotonin receptors seemed to
eliminate the hypotensive reﬂex during acute hemorrhage
[10]. Accumulationof extracellular serotonin by SSRIsresult
in downregulation of neuronal transmission, thus blunting
the eﬀect of the neurocardiogenic reﬂex.
Paroxetine was studied in a randomized, double-blind,
placebo-controlled trial in patients who suﬀered from
recurrent vasovagal syncope (VVS) [11]. 68 consecutive
patients were included and those that received paroxetine
were signiﬁcantly less likely to suﬀer from spontaneous
syncope (17.6% in the paroxetine group compared to 52.9%
in the placebo group) over a mean follow-up period of 25.4
months. Similar results were reported in studies evaluating
other SSRIs including ﬂuoxetine [12] and sertraline [13].
Despite success in these small trials, until their results
can be duplicated in larger trials, the European Society of
Cardiology is not currently recommending use of this class
of agents.
Besides pharmacologic therapy, much eﬀort has been
devoted to examining whether pacemaker insertion is useful
in treating various forms of neurally mediated syncope,
and in particular vasovagal syncope. Five major multicenter
randomized controlled trials have been done so far to
evaluate the beneﬁt of pacing in this patient population
[14–18].
The ﬁrst three studies [14–16] published showed a
signiﬁcant beneﬁt to patients who were implanted with a
pacemaker. The two most recent studies, however, showed
a negative result. The largest diﬀerence in these studies
was the method in which they were conducted. The initial
three studies, theVPS Study [14], European VASIS trial [15]
and SYDIT trial [16] were all unblinded studies. Patients
were randomized to receive either a pacemaker or standard4 Cardiology Research and Practice
medical therapy. In the latter two studies, the SYNPACE
trial [17]a n dt h eV P SI Is t u d y[ 18], all patients received
a pacemaker, but patients were randomized to have their
device either turned on or turned oﬀ.
Combining the data of these ﬁve trials, only 318 patients
are studied. In addition, because the ﬁrst three trials were
unblinded, placebo eﬀect and reporting bias must be taken
into consideration when examining the results of these
studies. While pacing may be eﬃcacious for the bradycardic
component of neurally mediated syncope, it does little to
combat the accompanying hypotension. Thus, given the
evidence, pacing therapy is not considered ﬁrst line therapy
for most patients with neurally mediated syncope, and the
European guidelines state “cardiac pacing should be limited
as a choice of last resort to a very selected small proportion
of patients aﬀected by severe vasovagal syncope [6].” In the
subject of this case report, the vasodepressor component of
his syncope overshadowed the cardioinhibitory component,
thus pacing was not considered to be a reasonable treatment
choice for this individual.
2.3. Treatment of Syncope in Cancer Patients. Recurrent
carotid sinus syncope in head and neck cancer patients is
uncommon but can present a particularly malignant form
of the condition. The presumed mechanism is direct tumor
compression of the carotid sinus baroreceptors or CN IX, or
both, as in the case above. There are no guidelines currently
in place to direct the treatment for syncope in this speciﬁc
patient population. Several case reports have been published
with circumstances similar to those seen in our patient.Most
recently,twogroupsreportedresolutionofsyncopalepisodes
with tumor regression with chemotherapy [19, 20]. In one
case, the patient had a pacemaker placed but continued
to faint. However, in both cases symptoms resolved after
induction chemotherapy was begun.
Older published reports have also documented similar
situations. One case report examined a group of 17 patients
suﬀering from head and neck carcinoma with associated
syncope [21]. Various treatment strategies including carotid
ligation,intracranial sectioning ofCNIX,andlocalradiation
have been employed with success in individual reports.
Of the 17 patients, three had pacemakers placed and this
appeared to be ineﬀective in preventing syncope. Another
report with seven patients found periarteriectomy, intracra-
nial nerve rootsection, and radiation therapy to be beneﬁcial
[22].
A review from the neurosurgery literature examines
treating CN IX dysfunction by surgical means. A group
from France investigated patients who were suﬀering from
syncopal episodes secondary to tumor compression of CN
IX [23]. The majority of these patients were treated with
neurosurgical resection of the root of CN IX, though not all
surgeries were completely curative. In addition to discussing
surgical options for these types of patients, the authors also
discuss the importance of relief of symptoms with treatment
of the underlying cause-invading tumor.
What many of these successfully treated cases have in
common is achievement of regression of the underlying car-
cinoma, reductionintumorburden,and reliefofpressure on
either the carotid baroreceptors, CN IX, or both. Pacemaker
implantation has been an unsuccessful treatment strategy
in this group of patients, due to a pacemaker’s inability to
combat the vasodilatory component of neurally mediated
syncope. Other medical treatment options, like those tried
in this patient, are often left to the discretion of the treating
physician because there are no current treatment guidelines
available. Deﬁnitive treatment and successful syncope relief
depends primarily on successful tumor regression, without
which the condition is likely to be inexorably disabling and
perhaps fatal.
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